Pharmaceuticals company Solara Active Pharma Sciences announced Q1FY26 results Q1FY26 Revenue at Rs 3,201 million vs Rs 3,641 million in Q1FY25; down by 12% YoY. Q1FY26 Gross Margin at Rs 1,732 million (54.1%) vs Rs 1,622 million (44.5%) in Q1FY25 and Rs 1,605 million (57.5%) in Q4FY25, Significant improvement by 960 bps YoY. Operating Costs at Rs 1,157 million in Q1FY26 vs Rs 1,200 million in Q1FY25 and Rs 1,095 million in Q4FY25; reduced by Rs 43 million YoY. Q1FY26 EBITDA at Rs 575 million (18%) vs Rs 422 million (11.6%) in Q1FY25 and Rs 510 million (18.3%) in Q4FY25; Significant improvement by 639 bps YoY. Gross Debt as on 30-Jun-25 at Rs 6,327 million vs Rs 7,760 million in FY25; reduced by Rs 1,433 million. Q1FY26 PAT at Rs 105 million; Highest in the last 12 quarters. Sandeep Rao, MD & CEO, said: We kickstarted our journey into FY26 with an objective of repivoting the business from Reset to a Sustainable, Scalable and Reliable Growth and I am glad to share that we have started this journey on the right note. The Revenues have grown QoQ by ~15% with a healthy margin profile resulting in QoQ Margin growth of 8%. Although the Opex on a QoQ basis reflects a marginal increase with respect to the increased level of operations, the Business clocked EBITDA growth of ~13% on QoQ basis. Regulated markets and a healthy product mix continue to be a consistent feature of the business. We continue to work towards reducing our Debt through a combination of Rights issue and operating leverage resulting in a lighter and healthier balance sheet. Solara has recorded the highest PAT in the last 12+ quarters on account of EBITDA growth led by positive business outcomes and reduced finance cost. Result PDF